Scarica l'app Stockscreener
23.76
1.70%
-0.41
Dopo l'orario di chiusura:
23.66
-0.10
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Schrodinger Inc Borsa (SDGR) Ultime notizie
Schrödinger, Inc. (NASDAQ:SDGR) Q1 2025 Earnings Call Transcript - Insider Monkey
Schrödinger First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Schrödinger, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... - Yahoo Finance
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Advancements - GuruFocus
Decoding Schrodinger Inc (SDGR): A Strategic SWOT Insight - GuruFocus
Schrödinger Q1 2025 slides: revenue jumps 63%, clinical readouts on horizon - Investing.com Canada
Schrödinger projects strong 2025 revenue growth with $45M-$50M in drug discovery - MSN
Schrodinger Inc (SDGR) Q1 2025 Earnings: Revenue Surges to $59.6M, Beating Estimates; Net Loss Widens to $59.8M - GuruFocus
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Schrodinger Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Schrodinger Q1 2025 beats EPS expectations, stock rises - Investing.com
Schrodinger (SDGR) Surpasses Revenue Expectations with Strong Gr - GuruFocus
Schrodinger (SDGR) Reaffirms 2025 Financial Projections | SDGR Stock News - GuruFocus
Earnings Flash (SDGR) SCHRODINGER Reports Q1 Revenue $59.6M, vs. FactSet Est of $54.7M - marketscreener.com
Schrodinger earnings beat by $0.10, revenue topped estimates - Investing.com
Schrödinger Reports Strong First Quarter 2025 Financial Results - Eagle-Tribune
Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)? - Yahoo Finance
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - Benzinga
Schrödinger to Present at BofA Securities 2025 Healthcare Conference - 01net
Schrödinger to Present at BofA Securities 2025 Healthcare Conference | SDGR Stock News - GuruFocus
Learn to Evaluate (SDGR) using the Charts - news.stocktradersdaily.com
Top 5 AI & Digital Biotech Companies (May 2025) - Securities.io
Schrödinger Demonstrates Corporate Sustainability Progress in 2024 Report - ReportAlert
Schrodinger Inc (SDGR) Shares Gap Down to $25.585 on Apr 28 - GuruFocus
Schrödinger, Inc. (NASDAQ:SDGR) Looks Just Right With A 33% Price Jump - simplywall.st
Schrödinger Presents New Preclinical Data at AACR Annual Meeting - 01net
Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential - Insider Monkey
Schrödinger to Announce First Quarter 2025 Financial Results on May 7 | SDGR Stock News - GuruFocus
Schrödinger to Announce First Quarter 2025 Financial Results on May 7 - marketscreener.com
3 Momentum Stocks That Could Soar Post-Market Volatility - MarketBeat
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger (NASDAQ:SDGR) shareholders are up 29% this past week, but still in the red over the last five years - simplywall.st
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? - MSN
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued - Yahoo Finance
Schrodinger price target raised to $32 from $30 at KeyBanc - TipRanks
Schrodinger’s Karen Akinsanya sells $419,570 in stock By Investing.com - Investing.com South Africa
Schrodinger’s Karen Akinsanya sells $419,570 in stock - Investing.com
Schrodinger issues statement on FDA phasing out animal testing requirement - TipRanks
FDA recent move marks paradigm shift in drug development, boosting Schrödinger (SDGR) and other biotech stocks - Investorsobserver
Schrodinger (SDGR) Backs FDA's Initiative to Cut Animal Testing in Drug Development | SDGR Stock News - GuruFocus
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal T - GuruFocus
Schrödinger backs FDA’s move away from animal testing By Investing.com - Investing.com South Africa
Schrodinger to Launch Predictive Toxicology Tool in H2 - marketscreener.com
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - 01net
0.08%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):